Auditory system adverse events with sacubitril/valsartan: an active-comparator restricted disproportionality analysis using the FDA adverse event reporting system database
Sacubitril/valsartan may be associated with a higher risk of auditory AEs than lisinopril and losartan. These findings warrant further confirmation through pharmacoepidemiologic studies.
Authors
- Niaz Chalabianloo (ORCID: https://orcid.org/0000-0001-7228-4725)
- Flory Tsobo Muanda (ORCID: https://orcid.org/0000-0003-4682-6564)
- Atefeh Jafari (ORCID: https://orcid.org/0000-0001-5782-3559)
Institutions
- Western University (CA)
- London Health Sciences Centre (CA)
- Kidney Associates (US)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1080/14740338.2025.2568242
- Citations
- 1
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 1.39